The closing price of Aclaris Therapeutics Inc (NASDAQ: ACRS) was $1.19 for the day, down -0.83% from the previous closing price of $1.20. In other words, the price has decreased by -$0.0100 from its previous closing price. On the day, 1945670 shares were traded.
Ratios:
Our analysis of ACRS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.16 and its Current Ratio is at 4.16. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 03, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $22.Evercore ISI initiated its Outperform rating on October 03, 2023, with a $22 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 23 when Monahan Joseph sold 6,000 shares for $5.08 per share. The transaction valued at 30,460 led to the insider holds 129,724 shares of the business.
Balthaser Kevin bought 9,490 shares of ACRS for $74,971 on Sep 06. The Chief Financial Officer now owns 15,461 shares after completing the transaction at $7.90 per share. On Aug 28, another insider, Loerop James, who serves as the Chief Business Officer of the company, bought 14,705 shares for $6.80 each. As a result, the insider paid 99,959 and bolstered with 21,688 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 85.11M and an Enterprise Value of -33.57M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.70 while its Price-to-Book (P/B) ratio in mrq is 0.54. Its current Enterprise Value per Revenue stands at -1.07 whereas that against EBITDA is 0.29.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $12.93, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 1.1382, while the 200-Day Moving Average is calculated to be 5.4822.
Shares Statistics:
ACRS traded an average of 2.42M shares per day over the past three months and 1.31M shares per day over the past ten days. A total of 70.89M shares are outstanding, with a floating share count of 64.47M. Insiders hold about 8.99% of the company’s shares, while institutions hold 89.32% stake in the company. Shares short for ACRS as of Feb 15, 2024 were 5.83M with a Short Ratio of 2.42, compared to 6.36M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.24% and a Short% of Float of 9.49%.
Earnings Estimates
The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$0.31 for the current quarter, with a high estimate of -$0.25 and a low estimate of -$0.37, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.23 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.75 and -$2.13 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$1.21, with 8 analysts recommending between -$0.36 and -$3.18.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $37.1M, while the lowest revenue estimate was $2.26M, resulting in an average revenue estimate of $9.79M. In the same quarter a year ago, actual revenue was $31.25M, down -68.70% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $11.29M in the next fiscal year. The high estimate is $40.8M and the low estimate is $2.26M. The average revenue growth estimate for next year is up 15.30% from the average revenue estimate for this year.
